Cargando…

Assessment of fibroblast growth factor 19 as a non-invasive serum marker for hepatocellular carcinoma

BACKGROUND: Fibroblast growth factor 19 (FGF-19) is one of the founding members of the endocrine FGF subfamily. Recently, it has been the subject of much interest owing to its role in various physiological processes affecting glucose and lipid metabolism and the regulation of bile acid secretion as...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohamed, Ghada Abdelrahman, Nashaat, Ehab Hasan, Fawzy, Hadeer Mohamed, ElGhandour, Ahmed Mohamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9055196/
https://www.ncbi.nlm.nih.gov/pubmed/35582295
http://dx.doi.org/10.4254/wjh.v14.i3.623
_version_ 1784697352406171648
author Mohamed, Ghada Abdelrahman
Nashaat, Ehab Hasan
Fawzy, Hadeer Mohamed
ElGhandour, Ahmed Mohamed
author_facet Mohamed, Ghada Abdelrahman
Nashaat, Ehab Hasan
Fawzy, Hadeer Mohamed
ElGhandour, Ahmed Mohamed
author_sort Mohamed, Ghada Abdelrahman
collection PubMed
description BACKGROUND: Fibroblast growth factor 19 (FGF-19) is one of the founding members of the endocrine FGF subfamily. Recently, it has been the subject of much interest owing to its role in various physiological processes affecting glucose and lipid metabolism and the regulation of bile acid secretion as well as cell proliferation, differentiation, and motility. Additionally, FGF-19 secretion in an autocrine style has reportedly contributed to cancer progression in various types of malignancies including hepatocellular carcinoma (HCC). AIM: To estimate the serum FGF-19 concentrations in HCC cases and assess its diagnostic performance for the detection of HCC. METHODS: We recruited 90 adult participants and divided them into three equal groups: Healthy controls, cirrhosis patients, and HCC patients. Serum FGF-19 concentrations were measured using the Human FGF-19 ELISA kit. RESULTS: We detected a high statistically significant difference in serum FGF-19 levels among the three groups. The highest level was observed in the HCC group, followed by the cirrhosis and control groups (236.44 ± 40.94 vs 125.63 ± 31.54 vs 69.60 ± 20.90 pg/mL, respectively, P ≤ 0.001). FGF-19 was positively correlated with alpha fetoprotein (AFP; r = 0.383, P = 0.003) and international normalised ratio (r = 0.357, P = 0.005), while it was negatively correlated with albumin (r = -0.500, P ≤ 0.001). For the detection of HCC, receiver operating characteristic curve analysis showed that the best cut-off point of AFP was > 8.2 ng/mL with an area under the curve (AUC) of 0.78, sensitivity of 63.33%, specificity of 83.33%, positive predictive value (PPV) of 79.2%, negative predictive value (NPV) of 69.4%, and total accuracy of 78%. However, FGF-19 at a cut-off point > 180 pg/mL had an AUC of 0.98, sensitivity of 100%, specificity of 90.0%, PPV of 90.0%, NPV of 100%, and total accuracy of 98%. CONCLUSION: FGF-19 represents a possible novel non-invasive marker for HCC. It may improve the prognosis of HCC patients due to its utility in several aspects of HCC detection and management.
format Online
Article
Text
id pubmed-9055196
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-90551962022-05-16 Assessment of fibroblast growth factor 19 as a non-invasive serum marker for hepatocellular carcinoma Mohamed, Ghada Abdelrahman Nashaat, Ehab Hasan Fawzy, Hadeer Mohamed ElGhandour, Ahmed Mohamed World J Hepatol Observational Study BACKGROUND: Fibroblast growth factor 19 (FGF-19) is one of the founding members of the endocrine FGF subfamily. Recently, it has been the subject of much interest owing to its role in various physiological processes affecting glucose and lipid metabolism and the regulation of bile acid secretion as well as cell proliferation, differentiation, and motility. Additionally, FGF-19 secretion in an autocrine style has reportedly contributed to cancer progression in various types of malignancies including hepatocellular carcinoma (HCC). AIM: To estimate the serum FGF-19 concentrations in HCC cases and assess its diagnostic performance for the detection of HCC. METHODS: We recruited 90 adult participants and divided them into three equal groups: Healthy controls, cirrhosis patients, and HCC patients. Serum FGF-19 concentrations were measured using the Human FGF-19 ELISA kit. RESULTS: We detected a high statistically significant difference in serum FGF-19 levels among the three groups. The highest level was observed in the HCC group, followed by the cirrhosis and control groups (236.44 ± 40.94 vs 125.63 ± 31.54 vs 69.60 ± 20.90 pg/mL, respectively, P ≤ 0.001). FGF-19 was positively correlated with alpha fetoprotein (AFP; r = 0.383, P = 0.003) and international normalised ratio (r = 0.357, P = 0.005), while it was negatively correlated with albumin (r = -0.500, P ≤ 0.001). For the detection of HCC, receiver operating characteristic curve analysis showed that the best cut-off point of AFP was > 8.2 ng/mL with an area under the curve (AUC) of 0.78, sensitivity of 63.33%, specificity of 83.33%, positive predictive value (PPV) of 79.2%, negative predictive value (NPV) of 69.4%, and total accuracy of 78%. However, FGF-19 at a cut-off point > 180 pg/mL had an AUC of 0.98, sensitivity of 100%, specificity of 90.0%, PPV of 90.0%, NPV of 100%, and total accuracy of 98%. CONCLUSION: FGF-19 represents a possible novel non-invasive marker for HCC. It may improve the prognosis of HCC patients due to its utility in several aspects of HCC detection and management. Baishideng Publishing Group Inc 2022-03-27 2022-03-27 /pmc/articles/PMC9055196/ /pubmed/35582295 http://dx.doi.org/10.4254/wjh.v14.i3.623 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Observational Study
Mohamed, Ghada Abdelrahman
Nashaat, Ehab Hasan
Fawzy, Hadeer Mohamed
ElGhandour, Ahmed Mohamed
Assessment of fibroblast growth factor 19 as a non-invasive serum marker for hepatocellular carcinoma
title Assessment of fibroblast growth factor 19 as a non-invasive serum marker for hepatocellular carcinoma
title_full Assessment of fibroblast growth factor 19 as a non-invasive serum marker for hepatocellular carcinoma
title_fullStr Assessment of fibroblast growth factor 19 as a non-invasive serum marker for hepatocellular carcinoma
title_full_unstemmed Assessment of fibroblast growth factor 19 as a non-invasive serum marker for hepatocellular carcinoma
title_short Assessment of fibroblast growth factor 19 as a non-invasive serum marker for hepatocellular carcinoma
title_sort assessment of fibroblast growth factor 19 as a non-invasive serum marker for hepatocellular carcinoma
topic Observational Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9055196/
https://www.ncbi.nlm.nih.gov/pubmed/35582295
http://dx.doi.org/10.4254/wjh.v14.i3.623
work_keys_str_mv AT mohamedghadaabdelrahman assessmentoffibroblastgrowthfactor19asanoninvasiveserummarkerforhepatocellularcarcinoma
AT nashaatehabhasan assessmentoffibroblastgrowthfactor19asanoninvasiveserummarkerforhepatocellularcarcinoma
AT fawzyhadeermohamed assessmentoffibroblastgrowthfactor19asanoninvasiveserummarkerforhepatocellularcarcinoma
AT elghandourahmedmohamed assessmentoffibroblastgrowthfactor19asanoninvasiveserummarkerforhepatocellularcarcinoma